Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
| Autor: | Palma Maurizi, Cesare Colosimo, Vita Ridola, Riccardo Riccardi, Daniela Rizzo, Maria Scalzone, Antonio Ruggiero, Stefano Mastrangelo, Giorgio Attinà, Massimo Caldarelli, Ilaria Lazzareschi, Mario Balducci |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Male Children medicine.medical_treatment Rome Hospitals University Hospitals Religious Brain Stem Neoplasms Pharmacology (medical) Prospective Studies Child Neurons Glioma Prognosis Dacarbazine Infectious Diseases Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA Chemotherapy Adjuvant Child Preschool Toxicity Disease Progression Female Adjuvant medicine.drug Diffuse intrinsic pontine glioma medicine.medical_specialty Adolescent Newly diagnosed Internal medicine medicine Temozolomide Humans Antineoplastic Agents Alkylating Pharmacology Chemotherapy business.industry medicine.disease Survival Analysis Surgery Radiation therapy Neoplasm Grading business Progressive disease Chemoradiotherapy Brain Stem Follow-Up Studies |
| Zdroj: | Journal of chemotherapy (Florence, Italy). 27(2) |
| ISSN: | 1973-9478 |
| Popis: | Background: The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG). Methods: Patients younger than 18 years with newly diagnosed DIPG were enrolled. Children were treated with focal RT along with concurrent daily TMZ. Four weeks after completing the initial RT–TMZ schedule, adjuvant TMZ was given every 28 days up to 12 cycles or progression disease. Results: Fifteen children with a median age of 9 years were enrolled. Fourteenth out of the 15 patients completed the chemoradiotherapy. The toxicity associated with TMZ was primarily haematopoietic. At a median follow-up of 15 months 13 children had died and 2 children were alive with progressive disease. No patient experienced complete response (CR). The median time to progression was 7·15 months. Conclusion: Chemoradiotherapy with TMZ followed by adjuvant TMZ did not improve the poor prognosis asso... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|